REVIEW

Innovation in Atopic Dermatitis: From Pathogenesis to Treatment

M. Munera-Campos,* J.M. Carrascosa

Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain

Received 5 July 2019; accepted 4 November 2019

KEYWORDS

Atopic dermatitis; Pathogenesis; Biologics; Dupilumab; JAK; Topical treatment

Abstract Atopic dermatitis is the most common inflammatory skin disease and up to 20% of cases can be classed as moderate to severe. Our understanding of the pathogenesis of this disease has improved in recent years. The process is primarily driven by the Th2 pathway, but with significant contributions from the Th22 pathway, the Th1 and Th17 axes, epidermal barrier dysfunction, pruritus, and JAK/STAT signaling. Advances in our understanding of the pathogenesis of atopic dermatitis have led to the development of new systemic treatments. Of particular note are biologic agents targeting IL-4 and IL-13 (e.g., dupilumab, tralokinumab, and lebrikizumab) and small molecules, such as JAK inhibitors (e.g., baricitinib, upadacitinib, and abrocitinib). Novel topical treatments include phosphodiesterase 4 and JAK/STAT inhibitors. In this article, we review the main advances in the treatment of atopic dermatitis. Characterization of clinical and molecular phenotypes with a key pathogenic role is essential for driving these advances.

© 2019 AEDV. Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Dermatitis atópica; Patogenia; Biológicos; Dupilumab; JAK; Tratamiento tópico

Innovación en dermatitis atópica: de la patogenia a la terapéutica

Resumen La dermatitis atópica (DA) es la dermatosis inamatoria más frecuente y hasta un 20% de los casos pueden clasificarse como moderados a graves. En los últimos años se ha producido un avance en el conocimiento de la patogenia, centrada en la vía Th2, pero con una participación marcada de la vía Th22 y de los ejes Th1 y Th17, de la disfunción de barrera epidérmica, el prurito, y la señalización JAK/STAT. Este progreso ha condicionado el desarrollo de nuevas terapias sistémicas, entre las que destacan fármacos biológicos dirigidos frente a la IL-4/13, como dupilumab, tralokinumab y lebrikizumab, pero también moléculas pequeñas,

* Corresponding author.
E-mail address: monicamunera@hotmail.com (M. Munera-Campos).

1578-2190/© 2019 AEDV. Published by Elsevier España, S.L.U. All rights reserved.
Introduction

Atopic dermatitis (AD) is the most common inflammatory skin disease, with an estimated prevalence of 10% to 15% in children and 2% to 10% in adults in the Western population. Up to 20% of cases of AD can be classiﬁed as moderate or severe according to the different clinical measurement scales, the most widely used of which include the Investigator Global Assessment (IGA), the Eczema Area and Severity Index (EASI), and the SCORing Atopic Dermatitis (SCORAD) scale.

Clinically, there is a notable phenotypic variability driven by a complex interaction between genetics, immune function, and the environment. In recent years, a revolution in translational research has extended knowledge of pathogenesis of AD and led to the development of new molecules targeting key in ammatory elements of the disease.

This article reviews key aspects in the pathogenesis of the disease with potential application for therapeutic targets.

Pathogenesis

AD is considered a model of imbalance between response of T helper (Th) lymphocytes 1 and 2, with predominance of Th2 response. Th2 lymphocytes produce interleukin (IL)-4 and IL-13, which inhibit the expression of “laggrin, thus establishing a relationship between immune dysfunction and disruption of barrier function typical in AD. In recent years, different translational studies have found the pathogenesis to pivot around Th2/Th22 response throughout the entire course of the disease, with a degree of participation of Th17, and with an additional contribution from the Th1 axis in the chronic phase.

However, the above framework is obviously a simpliﬁed version of the contribution of these responses is thought to vary according to disease subtype. Indeed, at least 3 immunological subtypes of AD have been characterized. In these subtypes, of note is the contribution of Th17 response, even though substantial Th2/Th22 activation is maintained. These 3 subtypes are pediatric AD, which shows a higher participation of innate immunity, IL-9, and IL-33; the intrinsic variant (20% in adults), which typically presents with normal levels of IgE and without personal or family history of atopy; and “nally the Asian phenotype, in which phenotypes with marked lichenoid cation or psoriasis-like phenotypes predominate.

There are also other potential participants in the pathogenic process. Thus, keratinocytes are an active element and produce cytokines, such as thymic stromal lymphopoietin (TSLP), able to induce expression of OX40L through activation of immature dendritic cells, and IL-33, which induces expression of OX40L through activation of type 2 innate lymphoid cells, and thus ampliﬁes Th2 response. These are the so-called alarmins, an element of innate immunity and rapid and potent ampliﬁers of in ammatory response.

IL-4 and IL-13 are implicated in the synthesis of IL-31, a key participant in the induction of pruritus, and IL-5, which mediates recruitment of Th2 and eosinophils. In addition, pruritus leads to scratching, thus facilitating skin barrier dysfunction and colonization by Staphylococcus aureus, in turn perpetuating Th2 response and overexpression of IL-4, IL-13, and IL-22. Greater colonization is facilitated by the lower expression of antimicrobial peptides in lesioned skin and apparently healthy skin of patients with AD, also associated with the IL-4/IL-13 pathway (Fig. 1).

In addition to identifying key molecules in the pathogenesis of AD and, therefore, potential therapeutic targets for speciﬁc monoclonal antibodies, other molecules implicated throughout the in ammatory process have also been shown to be important. Thus, participation of the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway activated by IL-4 has also been studied in the immune dysregulation in AD. The JAK family is formed by 4 members (JAK1, JAK2, JAK3, and tyrosine kinase 2 [TYK2]) and, unlike alopecia areata or psoriasis, all 4 participate in AD. The different elements of this family form part of the numerous cytoplasmic IL receptors (Fig. 2). Inhibition of these molecules, therefore, would have an impact on numerous IL molecules implicated in Th2 response and eosinophil activation.

Better knowledge of the in ammatory pathways in AD as well as the pathways implicated in pruritus has led to the development of drugs that speciﬁcally target different cytokines as well as drugs with broad action targeting intracellular signaling, with an impact on the “nal production of different cytokines.

Systemic Treatments

Biologic Agents

Th2 Cell Response Antagonists (IL-4 and IL-13)
Blockade of the IL-4/IL-13 Pathway. IL-4 and IL-13 are key elements in Th2 response. They trigger and control immune response in AD, such that speciﬁc antagonism of these cytokines has revolutionized therapeutics in this disease.

Dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 by blocking the α subunit shared by the receptors of
Innovation in Atopic Dermatitis: From Pathogenesis to Treatment

Figure 1  Biologic agents and specific targets in the pathogenesis of atopic dermatitis.
Abbreviations: IgE, immunoglobulin E; IL, interleukin; OSMRβ; oncostatin M receptor β; Th, T helper (lymphocyte); TSLP, thymic stromal lymphopoietin.

Figure 2  Small molecules and specific targets in the pathogenesis of atopic dermatitis.
Abbreviations: AC, adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; CREB, cAMP response element-binding protein; DGLA, dihomoly-linolenic acid; H4R, histamine 4 receptor; IL, interleukin; JAK, Janus kinase; kOR, k-opioid receptor; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NFAT, nuclear factor of activated T-cells; NK-1R, neurokinin 1 receptor 1; PDE4, phosphodiesterase 4; PGD1, prostaglandin D1; PGD2, prostaglandin D2; PGE1, prostaglandin E1; PKA, protein kinase A; STAT, signal transducer and activator of transcription; Th, T helper (lymphocyte); TSLP, thymic stromal lymphopoietin; TYK, tyrosine-kinase.

dupilumab 300 mg every 2 weeks for 16 weeks was superior to placebo for the primary outcome measure (IGA of 0 or 1: 38% and 36% for dupilumab compared with 10% and
8% for placebo, respectively).\textsuperscript{12} Dupilumab was also superior for all secondary outcome measures (EASI-75, reduction of pruritus, symptoms of anxiety and depression, quality of life, and need for rescue medication) compared with placebo.\textsuperscript{12,13} Another phase III RCT has also reported positive findings for dupilumab in combination with topical corticosteroids compared with placebo after 1 year of treatment (EASI-75: 65% for dupilumab 300 mg every 2 weeks compared with 22% for placebo; \( P = .001 \)).\textsuperscript{14} Two recent meta-analyses show superior effect of cacy of treatment compared with placebo, with similar benefit for regimens of 300 mg weekly or every 2 weeks. The main specic adverse effects were local injection site reactions to the drug and conjunctivitis.\textsuperscript{15,16} At present, 2 phase III RCTS in pediatric patients are in their nal stages.\textsuperscript{17,18} In March of 2019, the FDA extended the approval for dupilumab to adolescent patients aged 12 to 17 years.

Tralokinumab is a monoclonal antibody targeting IL-13. It competitively blocks binding to 2 different receptors: the heterodimeric receptor composed of IL-4R\( \alpha \) (antagonized by dupilumab) and IL-13R\( \alpha 1 \), and the decoy receptor IL-13R\( \alpha 2 \), which mediates endogenous regulation of IL-13. This pathway enables assessment, therefore, of the extent to which inhibition of IL-4 may be redundant compared with IL-13 in the pathogenesis of the disease.\textsuperscript{19} In a phase IIb RCT with 204 adults patient with moderate to severe AD, administration of tralokinumab at a dose of 300 mg every 2 weeks for 12 weeks achieved a decrease in EASI compared with placebo (mean baseline-adjusted change of \(-15.7%\) vs. \(-10.8\); \( P = .011 \)) and a higher percentage of patients had IGA 0 or 1 (26.7% vs. 11.8%). These results also show a high response to placebo, probably because of the concomitant use of topical corticosteroids in this RCT. There was also a signicant improvement in SCORAD, the Dermatology Life Quality Index, and pruritus.\textsuperscript{20} Currently, phase III RCTS are ongoing with tralokinumab in adults\textsuperscript{21} and adolescent patients.\textsuperscript{22}

Lebrikizumab is another monoclonal antibody that targets IL-13. It binds to soluble IL-13 and inhibits binding to IL-4R\( \alpha \).\textsuperscript{23} In a phase II RCT in 209 patients with moderate to severe AD, the group treated with lebrikizumab 125 mg every 4 weeks presented a greater percentage of EASI-50 responders than the placebo-treated group (82.4% vs. 62.3%; \( P = .026 \)). Once again, there were notable responses in the placebo group, and these could be attributed to the concomitant use of topical corticosteroids.\textsuperscript{24} At present, a trial is ongoing to assess efacy at a dose of 250 mg every 2 and 4 weeks.\textsuperscript{25}

Specic blockade of IL-13 has also been assessed in asthma, with modest improvements for tralokinumab and lebrikizumab.\textsuperscript{25,26,27} As is the case for AD, response may be greater in those patients with higher concentrations of markers related to IL-13.\textsuperscript{20} However, RCTS with monotherapy are needed to assess the utility of IL-13 blockade on its own.

**Blockade of Induction of Th2 Response: TSLP, OX40L, and IL-33.** The Th2 axis also includes the TSLP pathway, key in the interaction between the epidermis and innate and adaptive immune activation, given that an amatory response leads to an allergic phenotype through activation of immature dendritic cells that express OX40L, thus permitting polarization towards a Th2 response.\textsuperscript{28} Similarly, IL-33, produced by epithelial cells, can positively regulate the TSLP-dendritic cell-OX40L axis, participating in the induction and maintenance of Th2 response.\textsuperscript{29,30} Inhibition of this pathway could be interesting from the point of view of early treatment, given its participation in initial Th2 response.

Tezepelumab is an anti-TSLP monoclonal antibody that was recently assessed in a phase II RCT without showing superior efacy to placebo after 16 weeks.\textsuperscript{31} At present, another dose-rding RCT is ongoing with tezepelumab (NCT03809663). Another molecule, MK-8226, antagonist of the TSLP receptor, was assessed in a phase I RCT at different intravenous doses; a signicant decrease in EASI at a dose of 3 mg/kg compared with placebo at 12 weeks was observed (10.20 vs. 0.38; \( P = .015 \)).\textsuperscript{32}

A monoclonal antibody against OX40, GBR 830, has been tested at an intravenous dose of 10 mg/kg/4 weeks for 2 months against placebo with positive results.\textsuperscript{33} At present, RCTS with another OX40 inhibitor, the KHR4093 molecule (NCT03096223 and NCT03703102), and with etokimab/ANB020, an anti-IL-33 antibody (NCT03533751) are ongoing.

**Antagonism of Th22 Response** Th22 lymphocytes are the main IL-22 producers and they participate in both acute and chronic forms of AD. IL-22 can increase barrier dysfunction, induce epidermal hyperplasia, and inhibit proteins that are important in normal keratinization, such as laggrin.\textsuperscript{34}

In a phase Ia RCT, the use of fezakinumab (IVL-094), an anti-IL-22 agent, at a dose of 300 mg every 2 weeks achieved an improvement (measured as a decrease on the SCORAD scale), although not a signicant one, compared with placebo in patients with moderate to severe AD. The subanalysis of patients with severe AD did show signicant differences in the reduction of Body Surface Area (BSA) and IGA.\textsuperscript{35} The bene-cient achieved with this drug might be limited to patients with worse response to Th2 blockade and with higher expression of Th22,\textsuperscript{36} although the evidence to date is limited.

**Antagonism of Th17 Response** As mentioned earlier, in the chronic phase of AD and in certain groups of patients, Th2 and Th22 response is sustained, but there is parallel activation of the Th1/Th17 axis.\textsuperscript{37} Recently, blockade of IL-17A and IL-17C has been studied. Although data on inhibition of this axis in AD are still very premature, development in this area is of interest given the therapeutic potential in certain AD subphenotypes.

Secukinumab, a selective inhibitor of IL-17A, approved in psoriasis, has recently been studied in a phase II RCT in AD (NCT03533751), with the induction regimen used in psoriasis and with a maintenance dose of 300 mg/4 weeks or intensi-ced to 300 mg/2 weeks. The results are pending publication.\textsuperscript{38}

In addition, there are ongoing studies (NCT03568071, NCT03689829, NCT03864627) with an anti-IL-17C antibody, MOR106, which could mediate a decrease in levels of IgE and Th2 cytokines.\textsuperscript{39}
Blockade of the IL-31 and OSMRβ Pathway (Pruritus Signaling)

IL-31 is a cytokine produced mainly by Th2 lymphocytes and is closely linked with pruritus in different cell types, including peripheral neurons. IL-31 binds to a heterodimeric receptor composed of an IL-31 receptor α (IL-31Rα) and oncostatin M receptor β (OSMRβ). Blockade, therefore, could also break the vicious circle of pruritus, scratching, and compromise of epidermal barrier function.

Nemolizumab blocks IL-31 receptor α (IL-31Rα). To date, a placebo-controlled phase II RCT in adults treated with nemolizumab (dose of 0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg every 4 weeks for 12 weeks) showed decreases in pruritus; however, improvement on the clinical scales was not statistically significant. Nemolizumab could be effective in reducing pruritus, as well as improving daily activities and work productivity, with an acceptable safety profile. At present, a dose-escalating RCT is pending completion (NCT03100344).

The phase I RCT (NCT01614756) that investigated the use of an anti-IL-31 agent (BMS-981164) was terminated early and the results were not published. It is therefore unknown whether the effects of blockade of IL-31 would be limited to an effect on the symptoms of pruritus, given that there was no significant improvement in the skin inflammation outcome measures.

In addition, a phase I/II RCT has been conducted with KPL-716, an anti-OSMRβ antibody that has demonstrated an improvement in EASI and in the pruritus scales compared with placebo.

IgE Antagonism

Omalizumab, an anti-IgE agent approved for the treatment of asthma, has been assessed in a meta-analysis; no evidence of overall effectiveness in adults with AD was found. Its use in pediatric patients is being assessed (NCT02300701).

Small Molecules

The group of small molecules includes orally administered agents that generate a broad reduction, although less specific, in the release of mediators. This strategy has advantages in AD as, unlike psoriasis, there is no evidence of a key molecule involved in the pathogenesis of the disease. However, the lower specificity could be associated with potential issues with safety.

Inhibition of the JAK-STAT Signaling Pathway

At present, there are 4 orally administered JAK inhibitors under study. Baricitinib antagonizes JAK 1 (associated with modulation of the cytokines IL-4, IL-6, IL-10, IL-13, IL-31, and IFN-γ) and JAK2 (which modulates the cytokines IL-5, IL-6, IL-23, IL-31, and IFN-γ). In a phase II RCT, administration of baricitinib at a dose of 4 mg/day orally in patients with moderate to severe AD was associated with a higher proportion of patients achieving EASI-50 compared with placebo (61% vs. 37%; P = .027) at 16 weeks, with good tolerability. Adverse effects reported included asymptomatic creatine kinase elevation, but there were no cases of thrombotic events or herpes zoster.

Upadacitinib (ABT-494) and abrocitinib (PF-04965842) are selective JAK1 inhibitors, and early results with these agents are promising. A phase IIb RCT studied the use of upadacitinib at doses of 7.5, 15, and 30 mg compared with placebo for 16 weeks. The decrease in EASI compared with baseline was 71%, 62%, and 39% for the doses of 30, 15, and 7.5 mg, respectively. These improvements were similar to those observed with dupilumab. At present, a phase III RCT is ongoing to evaluate the efficacy of upadacitinib in adults and adolescents (NCT03607422). Another phase IIb RCT assessed the use of abrocitinib at doses of 10, 30, 100 and 200 mg a day compared with placebo; the reductions in EASI were only significant for the 200 mg dose (82.6%; P < .001) and 100 mg dose (59%; P = .009) compared with placebo (35.2%). Several phase III RCTs are ongoing with abrocitinib at doses of 100 and 200 mg compared with placebo (NCT03349060, NCT03575871, NCT03627767, and NCT03422822), as well as a phase III RCT with dupilumab as the comparator (NCT03720470). Finally, ASN002 is a dual inhibitor of the JAK and SYK pathways. PAN-JAK inhibition impacts the signaling of several cytokines implicated in AD (IL-4, IL-13, IL-31, and IL-33), whereas SYK inhibition suppresses signaling of proinflammatory cytokines (IL-1β, IL-10, and IL-17). In a phase IIb RCT with ASN002, the percentage of patients who achieved EASI-50 at 28 days was higher than in placebo for doses of 40 and 80 mg.

Currently, phase III RCTs are ongoing with these 4 drugs.

Phosphodiesterase 4 Antagonism

Recently, treatment with phosphodiesterase 4 (PDE4), administered both topically and orally, has been investigated. In AD, PDE4 activity in different inflammatory cells is increased compared with healthy skin. PDE degrades cyclic adenosine monophosphate (cAMP), a molecule that in normal conditions inhibits the production of several proinflammatory cytokines such as IL-4, IL-32, and PGE-2. PDE4 antagonism has a broad and nonspecific action, as it elevates intracellular cAMP and enables a reduction in cytokine and chemokine release.

In a phase III study, apremilast at a dose of 40 mg/12 hours achieved a greater reduction in EASI than placebo (31.57% vs. 10.98%; P = .034). However, there were no statistically significant differences in EASI-50 or pruritus. At present, there are no new RCTs with apremilast in AD.

Histamine 4 Receptor Antagonism

In recent years, the role of histamine 4 receptor antagonism has been studied. This could in principle not only achieve an antipruritic effect but also an anti-inflammatory one, given that activation of the receptor in keratinocytes interferes in proliferation and barrier function.

In a phase II RCT with the histamine 4 receptor antagonist, JNJ-39758979, there were significant differences in the reduction of pruritus but not EASI. However, this RCT was terminated early due to 2 cases of severe neutropenia. Recently, the results have been published of a phase III RCT with another histamine 4 receptor antagonist, ZPL-3893787, with significant reductions compared with placebo for EASI, but no significant decrease in pruritus.

Neurokinin 1 Receptor Blockade

Substance P, a mediator in pruritus, binds mainly to the neurokinin 1 receptor, which is expressed both in the central pathways...
### Table 1  Summary of the New Systemic Treatments in Development and in Phases of Investigation for Atopic Dermatitis.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Target</th>
<th>Route of Administration</th>
<th>Severity</th>
<th>Phase</th>
<th>Status</th>
<th>Intervention</th>
<th>Effectiveness</th>
<th>Safety</th>
<th>Clinical Trials (ID)</th>
</tr>
</thead>
</table>
| **Biologic Agents**  
  *Th2 axis antagonism*  
  Speciﬁc IL-4/IL-13 antagonism  
  Dupilumab | IL-4, IL-13 (IL-4Rα) | SC                       | Moderate to severe | III<sup>a</sup> | Completed | Randomization 1:1:1 (dupilumab 300 mg/7 d vs. 300 mg/15 d vs. placebo)  
  For 16 weeks  
  *Dupilumab groups: loading dose of 600 mg on day 1*  
  Primary outcome measure: IGA 0-1  
  SOLO-1: 37% vs. 38% vs. 10%  
  SOLO-2: 36% vs. 36% vs. 8%  
  Significant improvement in EASI-75, BSA, SCORAD, GISS, pruritus, and quality of life | Injection site reactions  
  Conjunctivitis | NCT02277743  
  NCT02277769  
  NCT02612454  
  NCT03054428 |
| **Tralokinumab**  
  IL-13 (IL-13Rα1 and IL-13Rα2) | SC                       | Moderate to severe | IIb  
  III | Completed | Randomization 1:1:1:1 (tralokinumab 45, 150, and 300 mg/15 d vs. placebo)  
  Concomitant use of topical corticosteroids  
  Tralokinumab 300 mg: reduction in EASI (mean adjusted difference, −4.94; 95% CI −8.76 to −1.13; P = .01).  
  IGA 0-1: 26.7% vs. 11.8% for placebo.  
  Significant improvement in SCORAD, DLQI, and pruritus | Injection site reactions | NCT02347176  
  NCT03131648  
  NCT03160885  
  NCT03363854  
  NCT03526861 |
Table 1 (Continued)

<p>| Drug            | Therapeutic Target | Route of Administration | Severity       | Phase | Status  | Intervention                                                                 | Effectiveness                                                                 | Safety                                                                 | Clinical Trials (ID) |
|-----------------|--------------------|-------------------------|----------------|-------|---------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------|                                                                      |                      |
| Lebrikizumab    | IL-13              | SC                      | Moderate to severe | II    | Completed | Randomization 1:1:1:1 (lebrikizumab 125 mg [SD] vs. 250 mg [SD] vs. 125 mg/4 wk vs. placebo) Concomitant use of topical corticosteroids | Primary outcome measure EASI-50: lebrikizumab 125 mg/4 wk (82.4%) vs. placebo (62.3%); ( P = .026 ) | Injection site reactions Mild herpes-like reactions, peripheral eosinophilia | NCT02340234 NCT03443024 |
| Antagonism of Th2 polarization: TSLP, OX40 L, and IL-33 | Tezepelumab         | TSLP                    | Moderate to severe | IIa   | Completed | Randomization 1:1 (tezepelumab 280 mg/2 wk vs. placebo) Concomitant use of topical corticosteroids | EASI-50 (tezepelumab 64.7% vs. placebo 48.2%; ( P = .091 )) No statistically significant differences | Injection site reactions | NCT02525094 NCT03809663 |
| MK-8226         | TSLP-R             | IV                      | Moderate to severe | I     | Discontinued | Randomization 3:1 GBR 830 10 mg/kg vs. placebo days 1 and 29 | Percentage of patients who achieved EASI-50 with GBR 830 superior to placebo, but no statistically significant differences (44% vs. 20%). | Good tolerability | NCT02683928 NCT03568162 |
| GBR 830         | OX40               | IV SC                   | Moderate to severe | IIa   | Completed | KHK-4083 0.003 and 0.001 mg/kg and ascending doses up to 10 mg/kg | Tolerability, safety Good tolerability. The development of anti-KHK4083 antibodies was described |                                                                      |                       |
| KHK4083         | OX40               | IV                      | Moderate to severe | I     | Completed | KHK-4083 0.003 and 0.001 mg/kg and ascending doses up to 10 mg/kg | Tolerability, safety Good tolerability. The development of anti-KHK4083 antibodies was described |                                                                      |                       |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Target</th>
<th>Route of Administration</th>
<th>Severity</th>
<th>Phase</th>
<th>Status</th>
<th>Intervention</th>
<th>Effectiveness</th>
<th>Safety</th>
<th>Clinical Trials (ID)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etokinab (ANB020)</td>
<td>IL-33</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Active</td>
<td>Etokinab vs. placebo</td>
<td>-</td>
<td>-</td>
<td>NCT03533751</td>
</tr>
<tr>
<td><strong>Antagonism of Th22 response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fezakinumab</td>
<td>IL-22</td>
<td>IV</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 2:1 Fezakinumab 600 mg (day 0), followed by 300 mg/2 weeks (last administration week 10) vs. placebo</td>
<td>Decrease in SCORAD only in the subgroup of severe AD at 12 weeks (36.4% vs. 22.3%; ( P = .05 )) and at 20 weeks (46.2% vs. 22.6%; ( P &lt; .01 )). Not statistically significant overall (including moderate AD)</td>
<td>Nasopharyngitis</td>
<td>NCT01941537</td>
</tr>
<tr>
<td><strong>Antagonism of Th17 and IL-23 response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secukinumab</td>
<td>IL-17A</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Study in parallel with secukinumab (same regimen as for psoriasis) vs. placebo</td>
<td>Asssessment at 16 weeks. Results pending publication</td>
<td>Good tolerability</td>
<td>NCT02594098 NCT03568136</td>
</tr>
<tr>
<td>MOR106</td>
<td>IL-17C</td>
<td>IV</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Active</td>
<td>MOR106 at different doses vs. placebo</td>
<td>-</td>
<td>-</td>
<td>NCT03568071 NCT03689829 NCT03864627 NCT01806662</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>IL-12, IL-23 (p40)</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Cross-over study with ustekinumab (same regimen as for psoriasis) vs. placebo</td>
<td>Greater percentage of patients achieved SCORAD-50 response vs. placebo, but the difference was not statistically significant</td>
<td>Good tolerability</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Target</th>
<th>Route of Administration</th>
<th>Severity</th>
<th>Phase</th>
<th>Status</th>
<th>Intervention</th>
<th>Effectiveness</th>
<th>Safety</th>
<th>Clinical Trials (ID)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blockade of the IL-31 and OSMRβ pathway</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nemolizumab</td>
<td>IL-31RA</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1:1:1 Nemolizumab (0.1, 0.5, or 2 mg/kg, placebo)</td>
<td>Significant dose-dependent reductions in pruritus for nemolizumab (−63.1% for doses of 0.5 mg/kg vs. −20.9%). Improvement in EASI and SCORAD</td>
<td>Injection site reactions, nasopharyngitis</td>
<td>NCT01986933 NCT03100344</td>
</tr>
<tr>
<td><strong>IgE or IL-5 antagonism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omalizumab (approved for asthma)</td>
<td>IgE</td>
<td>IV</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Omalizumab Omalizumab vs. placebo in patients aged 4 to 19 years with IgE &gt; 300 KU/l</td>
<td>Results not published</td>
<td>Results not published</td>
<td>NCT01179529 NCT02300701</td>
</tr>
<tr>
<td>Ligelizumab (QGE031)</td>
<td>IgE (higher affinity than omalizumab)</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1:1:1 (ligelizumab/2 wk vs. placebo vs. CsA)</td>
<td>Results not published</td>
<td>Results not published</td>
<td>NCT01552629</td>
</tr>
<tr>
<td>Mepolizumab (approved in asthma)</td>
<td>IL-5</td>
<td>SC</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Discontinued (futility)</td>
<td>Mepolizumab 100 mg/4 wk vs. placebo</td>
<td>Early termination of trial after interim data analysis</td>
<td>Efficacy was not demonstrated.</td>
<td>NCT03055195</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Target</th>
<th>Route of Administration</th>
<th>Severity</th>
<th>Phase</th>
<th>Status</th>
<th>Intervention</th>
<th>Effectiveness</th>
<th>Safety</th>
<th>Clinical Trials (ID)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Small Molecules</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhibition of the JAK-STAT signaling pathway</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baricitinib</td>
<td>JAK1, JAK2</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Active</td>
<td>Randomization 1:1:1 (baricitinib 2 mg, 4 mg, placebo) once daily</td>
<td>EASI-50: higher proportion of patients for baricitinib 4 mg/d vs. placebo (61% vs. 37%; ( P = .027 )) at 16 weeks</td>
<td>Good tolerability (no cases of neoplasm or thrombotic or cardiovascular events), no cases of herpes zoster</td>
</tr>
<tr>
<td>Upadacitinib (ABT-494)</td>
<td>JAK1</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>IIb</td>
<td>Completed</td>
<td>Active</td>
<td>Randomization 1:1:1:1 (upadacitinib 7.5, 15 and 30 mg vs. placebo)</td>
<td>Mean reduction in EASI at 16 weeks for doses of 30/15/7.5 mg was 74%/62%/39% vs. placebo (23%); ( P &lt; .05 )</td>
<td>Good tolerability, Upper respiratory tract infection and acne.</td>
</tr>
<tr>
<td>Abrocitinib (PF-04965842)</td>
<td>JAK1</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>IIb</td>
<td>Completed</td>
<td>Active</td>
<td>Randomization 1:1:1:1:1 (abrocitinib 10, 30, 100, and 200 mg, placebo) once daily</td>
<td>Percentage IGA 0-1 and improvement of ( \geq 2 ) points compared with baseline, significantly greater for abrocitinib 200 mg/d vs. placebo (44.5% vs. 6.3%) at 12 weeks</td>
<td>Good tolerability, on case of eczema herpeticum and one of pneumonia</td>
</tr>
<tr>
<td>Drug</td>
<td>Therapeutic Target</td>
<td>Route of Administration</td>
<td>Severity</td>
<td>Phase</td>
<td>Status</td>
<td>Intervention</td>
<td>Effectiveness</td>
<td>Safety</td>
<td>Clinical Trials (ID)</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------------------------------------------------</td>
<td>----------------------------------------------------</td>
<td>----------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>ASN002</td>
<td>PAN-JAK (JAK1, JAK2, JAK3, TYK), SYK</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>I</td>
<td>Completed</td>
<td>Randomization 1:1:1:1 (ASN002 20, 40 and 80 mg vs. placebo) For 28 days Proportion of patients who achieved EASI-75 significantly greater for ASN002 40 mg (71.4%; P = .06) and for ASN002 80 mg (33.3%; P = .65) vs. placebo (22.2%)</td>
<td>Good tolerability</td>
<td>NCT03139981, NCT03531957</td>
<td></td>
</tr>
<tr>
<td><strong>PDE4 antagonism</strong></td>
<td><strong>Apremilast</strong></td>
<td><strong>PDE4</strong></td>
<td>PO</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Parallel design 1:1:1:1 (apremilast 30 mg/12 h, 40 mg/12 h vs. placebo/apremilast 30 mg/12 h vs. placebo/apremilast 40 mg/12 h) Significantly reduction in EASI compared with baseline at 12 weeks with apremilast 40 mg/12 h vs. placebo (31.57% vs. 10.98%; P = .034). No benefit in terms of EASI/50 or pruritus. No significant differences at 30 mg/12 h</td>
<td>Diarrhea, nausea, abdominal discomfort</td>
<td>NCT02087943</td>
</tr>
<tr>
<td>[0,1–10]</td>
<td><strong>H4R antagonism</strong></td>
<td><strong>JNJ-39758979</strong></td>
<td>PO</td>
<td>Moderate</td>
<td>II</td>
<td>Discontinued (adverse effects)</td>
<td>JNJ-39758979 300 or 100 mg vs. placebo once daily Early termination of the clinical trial</td>
<td>Two cases of neutropenia</td>
<td>NCT01497119</td>
</tr>
<tr>
<td>Drug</td>
<td>Therapeutic Target</td>
<td>Route of Administration</td>
<td>Severity</td>
<td>Phase</td>
<td>Status</td>
<td>Intervention</td>
<td>Effectiveness</td>
<td>Safety</td>
<td>Clinical Trials (ID)</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------</td>
<td>-------------------------</td>
<td>---------------------------</td>
<td>-------</td>
<td>--------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>ZPL389</td>
<td>H4R</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>ZPL-389 30 mg vs. placebo once daily</td>
<td>Significant improvement in EASI (50% vs. 27%). No significant differences in terms of pruritus</td>
<td>Good tolerability</td>
<td>NCT02424253, NCT03517566</td>
</tr>
<tr>
<td>[0,1–10]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[0,1–10]</td>
<td>NKR1 blockade</td>
<td>Serlopitant</td>
<td>NKR1</td>
<td>PO</td>
<td>Mild, mild, moderate, or severe</td>
<td>II Completed</td>
<td>Randomization 1:1:1 (serlopitant 1 mg vs. 5 mg vs. placebo) 6 weeks</td>
<td>Nonsignificant reduction in pruritus compared with placebo (−2.25 vs. −2.32 vs. −2.01)</td>
<td>Good tolerability</td>
</tr>
<tr>
<td>Trapiditant</td>
<td>NKR1</td>
<td>PO</td>
<td>Mild, mild, moderate, or severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1 (trapiditant 100 mg/24 h vs. placebo)</td>
<td>Nonsignificant reduction in pruritus compared with placebo No other results</td>
<td>Good tolerability</td>
<td>NCT02004041, NCT02651714, NCT03568331</td>
</tr>
<tr>
<td>[0,1–10]</td>
<td>kOR agonism</td>
<td>Asimadolin</td>
<td>kOR agonist</td>
<td>PO</td>
<td>Mild, mild, moderate, or severe</td>
<td>II Completed</td>
<td>Randomization 1:1 (asimadolin 2.5 mg/12 h vs. placebo/12 h)</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td>[0,1–10]</td>
<td>Other molecules</td>
<td>DS107</td>
<td>DGLA</td>
<td>PO</td>
<td>Moderate to severe</td>
<td>II Completed</td>
<td>Randomization 1:1:1 (DS107 1 g vs. 2 g vs. placebo) Once daily</td>
<td>Results not published</td>
<td>Results not published</td>
</tr>
</tbody>
</table>

Abbreviations, AD, atopic dermatitis; BSA, Body Surface Area; CsA, ciclosporin A; DGLA, dihomo-γ-linoleic acid; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; GISS, Global Individual Signs Score; H4R, histamine 4 receptor; IGA, Investigator Global Assessment; IL, interleukin; IV, intravenous; JAK, Janus kinase; kOR, kappa opioid receptor; NKR1, neurokinin receptor 1; PDE4, phosphodiesterase 4; PO, oral route; SC, subcutaneous; SCORAD, SCORing Atopic Dermatitis; SD, single dose; Th, (lymphocyte) T helper; TSLP, thymic stromal lymphopoietin; TYK, tyrosine-kinase.

Data mentioned explicitly in the table are derived from clinical trials (ID) with text underlined.

a Approved in adults Extension to use in adolescents ≥ 12 years approved by the FDA.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic target</th>
<th>Severity</th>
<th>Phase</th>
<th>Status</th>
<th>Intervention</th>
<th>Effectiveness</th>
<th>Safety</th>
<th>Clinical trials (ID)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topical Inhibitors of JAK/STAT Signaling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>PAN-JAK (more selective JAK1 and JAK3)</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1 Topical tofacitinib 2% vs. placebo</td>
<td>Improvement in EASI compared with baseline signif. greater than for vehicle (−81.7% vs. −29.9%; P &lt; .001). Significant improvements in PGA, BSA, and pruritus. Good tolerability. Pain/burning at injection site.</td>
<td>NCT02001181</td>
<td></td>
</tr>
<tr>
<td>Ruxolitinib</td>
<td>JAK1, JAK2</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Ruxolitinib at different concentrations vs. triamcinolone 0.1% vs placebo</td>
<td>Improvement in EASI compared to baseline signif. greater than placebo for the 1.5% dose, once or twice a day, and 0.5% dose once a day at 4 weeks (71.6%/67%/52.2% vs. 15.5%; P &lt; .001) Good tolerability.</td>
<td>NCT03011892, NCT03257644, NCT03745651, NCT03920852</td>
<td></td>
</tr>
<tr>
<td>Cerdulatinib (RVT-502)</td>
<td>PAN-JAK, SYK</td>
<td>–</td>
<td>I</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Delgocitinib (JTE-052)</td>
<td>PAN-JAK</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 2:2:2:2:1:1 (delgocitinib 0.25%, 0.5%, 1%, 3%, vehicle, tacrolimus 0.1%) twice daily</td>
<td>Improvement in EASI compared to baseline for all doses of delgocitinib (0.25%, 0.5%, 1%, and 3%) signif. greater than vehicle (−41.7%, −57.1%, −54.9%, −72.9% vs. 12.2%, respectively; P = .001). Reduction in pruritus Good tolerability.</td>
<td>JapicCTI-152887, NCT03725722, NCT03826901, NCT03683719</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Therapeutic target</td>
<td>Severity</td>
<td>Phase</td>
<td>Status</td>
<td>Intervention</td>
<td>Effectiveness</td>
<td>Safety</td>
<td>Clinical trials (ID)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-------</td>
<td>----------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>SNA-125</td>
<td>JAK3, TrkA</td>
<td></td>
<td>I/II</td>
<td>Completed</td>
<td>2 trials with identical intervention, patients ≥ 2 years Randomization 2:1 (crisaborol:vehicle) Application twice a day</td>
<td>Assessment at 4 weeks of IGA 0/1, with significant improvements compared with vehicle: 51.7% vs. 40.6%, P = .005; 48.5% vs. 29.7%, P &lt; .0019</td>
<td>Good tolerability</td>
<td>NCT0118766 NCT02118792 NCT01301508 NCT01602341 NCT01652885 NCT03233529 NCT03260595 NCT03250663 NCT01461941 NCT01799880 NCT02094235</td>
</tr>
<tr>
<td>Crisaborol</td>
<td>PDE4</td>
<td>Mild to moderate</td>
<td>III</td>
<td>Completed</td>
<td>Randomization 1:1 (E6005 0.2% vs. vehicle) Application twice a day</td>
<td>Assessment at week 12: significant reduction in EASI compared with baseline (P = .030) and SCORAD (P &lt; .001)</td>
<td>Good tolerability</td>
<td>NCT01301508</td>
</tr>
<tr>
<td>E6005</td>
<td>PDE4</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Comparison of AN2898 2% with placebo in active lesion vs. placebo in another active lesion Application twice a day</td>
<td>Significantly improvement in ADPS compared with baseline, higher proportion of lesions with total or partial clearance of ADPS ≤ 2; 48% vs. 33% in comparison with vehicle</td>
<td>Good tolerability</td>
<td>NCT01301508</td>
</tr>
<tr>
<td>AN2898</td>
<td>PDE4</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1:1 (MM36 0.3% vs. 1% vs. vehicle Application twice a day</td>
<td>Reduction in IGA of 0/1 or reduction of 2 points: MM36 1%: 20.9% vs. 2.7% for vehicle; P = .0165) at week 4. Decrease in EASI: OPA-15406 1%: 39% vs. 3% for vehicle; P = .005) at week 2</td>
<td>Good tolerability</td>
<td>NCT02068352 NCT02945657 NCT02914548 NCT03018691 NCT01702181 NCT02334787 NCT03961529</td>
</tr>
<tr>
<td>MM36 (OPA-15406)</td>
<td>PDE4</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Active</td>
<td>Reduction in pruritus at injection site No differences were observed in SCORAD, pruritus (VAS 100 mm) or TEWL at week 2</td>
<td>Reduction in pruritus at injection site No differences were observed in SCORAD, pruritus (VAS 100 mm) or TEWL at week 2</td>
<td>Good tolerability</td>
<td>NCT01856764</td>
</tr>
<tr>
<td>Ro’umilast</td>
<td>PDE4</td>
<td>Moderate</td>
<td>IIa</td>
<td>Completed</td>
<td>Randomization 1:1:1 Ro’umilast 0.5% vs. vehicle Application twice a day</td>
<td>Dose-dependent improvement in IGA of 0/1 or reduction of 2 points: Ro’umilast 0.5%: 16.7% vs. 6.4% for vehicle; P = .048) at week 4. Decrease in EASI: OPA-15406 1%: 40% vs. 25% for vehicle; P = .013) at week 2</td>
<td>Good tolerability</td>
<td>NCT01301508</td>
</tr>
<tr>
<td>Drug</td>
<td>Therapeutic target</td>
<td>Severity</td>
<td>Phase</td>
<td>Status</td>
<td>Intervention</td>
<td>Effectiveness</td>
<td>Safety</td>
<td>Clinical trials (ID)</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-------</td>
<td>----------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td><strong>Other Targets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omiganan</td>
<td>This is an AMP</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1:1:1 (omiganan 1%, 1.75%, 2.5%, vehicle) Application twice a day Randomization 1:1:1:1 (omiganan 1% twice daily, 1% once daily, 0.5% twice daily, 0.5% once daily, vehicle twice daily, vehicle once daily)</td>
<td>Assessment of SCORAD, EASI, and IGA at 7 weeks Results not published</td>
<td>Good tolerability Contact dermatitis (infrequent)</td>
<td>NCT03091426 NCT02456480</td>
</tr>
<tr>
<td>Tapinarof (GSK2894512)</td>
<td>AhR agonist</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1:1:1:1 (tapinarof 1% twice daily, 1% once daily, 0.5% twice daily, 0.5% once daily, vehicle twice daily, vehicle once daily)</td>
<td>Results not published</td>
<td>Good tolerability Contact dermatitis (infrequent)</td>
<td>NCT02564055 NCT01098734 NCT00837551</td>
</tr>
<tr>
<td>PR022</td>
<td>Hypochlorous acid</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Active</td>
<td>Randomization 1:1:1 (PR022 0.05%, 0.1%, vehicle) For 28 days</td>
<td>No results available</td>
<td>No results available</td>
<td>NCT03351777</td>
</tr>
<tr>
<td>SP14019/Cyclatop</td>
<td>Topical CsA</td>
<td>Mild to moderate</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1 Ciclosporin 5% solution vs. vehicle For 4 weeks Patients ≥ 2 years</td>
<td>Significant improvements in Cyclatop compared with vehicle in EASI (51.2% vs. 23.6%), ADNI (55.4% vs. 34%), and IGA (61.5%)</td>
<td>Good tolerability</td>
<td>NCT02865356</td>
</tr>
<tr>
<td>Q301/Zyleuton</td>
<td>CRTH2 antagonist</td>
<td>Moderate to severe</td>
<td>II</td>
<td>Completed</td>
<td>Randomization 1:1 Q301 as a cream (dose not stated) vs. placebo</td>
<td>Results not published</td>
<td>Results not published</td>
<td>NCT02426359 NCT03571620</td>
</tr>
<tr>
<td>VTP-38543</td>
<td>LXR agonist</td>
<td>Mild to moderate</td>
<td>I/II</td>
<td>Completed</td>
<td>Randomization 1:1:1:1 (VTP-38543 0.05%/12 h, 0.15%/12 h vs. vehicle without Transcutol/12 h, vs. VTP-38543 1%/12 h vs. vehicle without Transcutol/12 h) For 28 days</td>
<td>No significant reduction in EASI or SCORAD compared with vehicle</td>
<td>Good tolerability</td>
<td>NCT02655679</td>
</tr>
</tbody>
</table>

Abbreviations, ADSI Atopic Dermatitis Severity Index; AhR, aryl hydrocarbon receptor; AMP, antimicrobial peptide; BSA, Body Surface Area; CRTH2, prostaglandin 2 transmembrane receptor; CsA, ciclosporin A; EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment; LXR, liver X receptors; JAK, Janus kinase; PDE4, phosphodiesterase 4; PGA, physician global assessment; SCORAD, SCORing Atopic Dermatitis; SYK, spleen tyrosine kinase; TEWL, transepidermal water loss; TrkA, tyrosine receptor kinase-A; VAS, visual analog scale. Data mentioned explicitly in the table are derived from clinical trials (ID) with text underlined.
nervous system and in skin. Thus, an oral neurokinin 1 receptor antagonist such as aprepitant could potentially improve pruritus. However, use of this agent in AD does not seem to be beneficial. Other inhibitors of the neurokinin 1 receptor, tradjepitant and selrotipitant, are under study, although also with modest results.

Table 1 summarizes the main RTCs with the new systemic treatments, and Figs. 1 and 2 show the main therapeutic targets.

Topical Treatments

Despite progress in the development of systemic drugs, topical treatments continue to be essential both for barrier function repair and delivery of anti-inflammatory molecules. In addition to ointments, corticosteroids, and calcineurin inhibitors, new small molecules have been developed that can be used topically.

Topical Inhibitors of JAK/STAT Signaling

At present, topical inhibitors of the JAK/STAT pathway are under investigation. These include topical tofacitinib 2% and ruxolitinib 1.5%, and these agents appear to be effective at reducing EASI and pruritus. In a Japanese RCT, a PAN-JAK inhibitor also showed improvements in EASI that were larger than with vehicle alone, without significant adverse effects.

PDE4 Topical Inhibitors

Topical crisaborole 2% is the first PDE4 inhibitor approved in adults and children over 2 years of age with mild to moderate AD.Phase II RCTs demonstrated significant improvement in EASI and pruritus. In an ongoing study, topical aprepitant is being developed as a topical formulation for the treatment of AD. In a Phase II RCT, aprepitant demonstrated significant improvement in EASI and pruritus.

Topical treatments are ongoing with other PDE4 inhibitors, such as the molecules E6005 and AN2898. Ominagan. The decreased production of antimicrobial peptides in AD facilitates microbial colonization and infection, and increases in inflammatory response. Ominagan is an antimicrobial peptide, developed in a gel formulation, that is being studied in Phase II RCTs; although no evident adverse effects are available, good tolerability of the agent has been reported.

Tapinarof. Tapinarof is a nonsteroidal anti-inflammatory agent that acts as an agonist of the aryl hydrocarbon receptor, an action which may improve barrier function and limit TH2 response. In a Phase II study, the use of tapinarof 1% twice a day showed significant differences in IGA 0-1 and reduction of EASI, SCORAD, and BSA, compared with vehicle; the drug was well tolerated and there were 2 cases of contact dermatitis out of 165 patients treated.

PR022 (Hypochlorous acid). In a series of patients with AD, the use of topical hypochlorous acid at 0.008% and 0.002% in a hydrogel formulation was associated with a decrease in pruritus. It is thought that hypochlorous acid could lower the concentrations of different cytokines such as TNF-α, IL-17, IFN-γ, and histamine. A phase III study is being conducted in adults with mild-moderate AD (NCT03351777).

SP14019/Cyclaclop. SP14019/cyclaclop is a topical drug formulated as a cyclosporin 5% spray under study in a phase II RCT in patients aged more than 2 years (NCT02865356). The results, presented in the European dermatology congress in 2018, showed significant improvement in EASI and IGA compared with vehicle at 4 weeks, with good tolerability and limited systemic absorption.

Table 2 summarizes the topical drugs under investigation.

Conclusions

In recent years, a better understanding of the pathogenesis of AD extending beyond the TH2 axis has led to the development of new biologics and small molecules, administered both topically and systemically, that target key elements of inflammation. Although psoriasis is a reference for translational medicine given its similarities with AD, the results for AD are still some way off those achieved with psoriasis. Currently, there is still discussion as to whether the best strategy is to target speciﬁc elements of the inflammatory process via monoclonal antibodies, for example dupilumab, or use broader-action molecules with a less speciﬁc mechanism of action such as upadacitinib. Progress in the study of new therapies and stratification of AD into different subtypes and subphenotypes in the coming years is essential to develop effective, long-term treatments with an acceptable safety proﬁle, especially in the moderate to severe forms.

Conflicts of interest

J.M. Carrascosa has received speaker and consultant fees from Sanofi and as an investigator in clinical trials for Sanofi, Lilly, Leo-Pharma, Pzderm, and Amgen. M. Munera-Campos has participated as an investigator and received fees for clinical trials sponsored by Lilly, Leo-Pharma, and Pzderm.

References


51. Ohawa Y, Hirayama N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol Int. 2014;63:533–42.


